SIRT2 and breast carcinoma: Great potential for synergistic combinations of SIRT2 inhibitors with clinically approved drugs was revealed just recently by examining the role of SIRT2 inhibitors in overcoming drug resistance to dasatinib, doxorubicin, or paclitaxel in treatment of melanoma or specific subtypes of breast cancer cells [11,12,13].